

COMPOUND AUTHORIZATION AND CONSENT FOR PARTICIPATION IN A RESEARCH STUDY**YALE UNIVERSITY
YALE UNIVERSITY SCHOOL OF MEDICINE****Pilot Study Title: Examining the Effect of Novel E-cigarette Constituents and Determining Appropriate Concentrations among Adults****Principal Investigator (the person who is responsible for this research):**

Suchitra Krishnan-Sarin, PhD

S-208, 34 Park Street

New Haven, CT 06519

Phone Number: 203-974-7595**Research Study Summary:**

- We are asking you to join a research study.
- We plan to enroll 30 people in this research study.
- The purpose of this research study (pilot study) is to examine the effects of different e-cigarette cooling flavors on people's sensory experience.
- Study procedures will include an intake visit to determine if you are eligible and one lab session. At the lab session, we will ask participants to sample 16 different e-liquids with various levels of cooling flavors in them and rate how strong the flavor is. The e-liquids will not have nicotine in them.
- In total, the study will take participants 5.5 hours to complete. The intake will take about 2 hours and lab session will take about 3.5 hours.
- During the lab session, we may ask you to wear a silicone smartband, similar to a smartwatch or fitbit. You will wear this on the same arm that you use to vape the e-cigarette. The smartband is used to monitor movement to track e-cigarette puffing behavior.
- There are some risks from participating in this study. The possible risks are vaping an e-cigarette, being exposed to additives and flavorants in an e-cigarette, keeping study data confidential, collecting urine samples, and completing rating scales and assessments. We will describe these risks in detail in this consent.
- The study may have no benefits to you.
- Taking part in this study is your choice. You can choose to take part, or you can choose not to take part in this study. You can also change your mind at any time. Whatever choice you make, you will not lose access to your medical care or give up any legal rights or benefits.
- If you are interested in learning more about the study, please continue reading, or have someone read to you, the rest of this document. Take as much time as you need before you make your decision. Ask the study staff questions about anything you do not understand. Once you understand the study, we will ask you if you wish to participate; if so, you will have to sign this form.

Why is this study being offered to me?

We are asking you to take part in a research study because you are at least 18 years old, report being a current e-cigarette user who uses e-cigarettes that contain both nicotine and flavoring. We are looking for 30 participants to be part of this research study.

Who is paying for the study?

This study is funded by the Food & Drug Administration's (FDA) Center for Tobacco Products (CTP) and the National Institute of Drug Abuse (NIDA).

What is the study about?

The purpose of this study is to examine how different e-cigarette cooling flavors can influence adults' sensory experience.

What are you asking me to do and how long will it take?

If you agree to take part in this study, this is what will happen:

- **Intake Appointment.** This is an appointment to confirm if you are eligible for this study. You will come to the CT Mental Health Center at 34 Park Street, New Haven or the Substance Abuse Treatment Unit (SATU) at 1 Long Wharf Dr., New Haven for this appointment. We will read you this consent form and if you agree to participate, you will sign it. During this appointment, you will provide personal information, including your medical history and other health information and your history and current use of nicotine and tobacco products. We will collect this information by filling out questionnaires via Redcap (CRF 11 compliant) and by a member of our research team who has been trained in administration of sensory tasks.

We will collect your urine sample to verify that you are not currently using other drugs or are currently pregnant. Pregnant females will not be allowed to participate. If you test positive for any drugs aside from marijuana, you will not be paid for the visit and will have the opportunity to reschedule this appointment one time. Additionally, we will also test your urine sample to detect cotinine levels (a byproduct of nicotine), which will help us understand more about your current use of nicotine products. We may collect an additional urine sample to conduct a follow-up drug test before the lab session. Again, if you test positive for any drugs aside from marijuana, you will not be paid, and you will be considered ineligible for the lab session. Additionally, we will collect blood pressure, heart rate, spirometry (a measure of lung function), and pulse oximetry, which measures how well oxygen is being sent through the body. This is measured by using a clip-like device on your finger and is quick and painless. For all in person appointments, we ask that you do not bring any weapons to appointments you have with us. We also ask that you do not drink any alcoholic beverages for 12 hours prior to your appointment time. If we suspect that you may be intoxicated, we may do a breathalyzer, ask you to remain in the clinic until it is safe to leave, and may reschedule your appointment.

If you decide that you will be in this study, and you will be visiting the Connecticut Mental Health Center (CMHC) or the Substance Abuse Treatment Unit (SATU) as part of your study procedures, some information about your participation in this research study will become part of your CMHC/SATU medical record that identifies you. If you do not already have a medical record at CMHC/SATU, one will be made for your visit. This chart will say you are/were a research participant at the CMHC.

- **Lab Session.** If you are a female, we will use a urine sample to administer a pregnancy test at the lab session. You will be excluded if you are pregnant or nursing. All laboratory sessions will be conducted on weekdays; these sessions will be conducted at the J.B. Pierce Laboratory at 290 Congress Ave in New Haven, CT or West Campus Research Unit (WCRU) at 500 West Campus Dr. in West Haven, CT.

We will ask you to stop using all tobacco products (e.g., cigarettes, e-cigarettes) for 2 hours prior to lab session start.

If you decide to participate in this study and will be attending visits at West Campus, as a participant in this clinical research study involving the Yale-New Haven Hospital (YNHH), it is important for you to know that if you do not already have a medical record at YNHH, one will be made for your admission. In addition, you need to know that if you have ever been a patient at YNHH at any time, your previous medical records of other visits or admissions will become available to the researchers and to the staff of the West Campus when today's information is added into the medical record.

At the beginning of the lab session, we will collect blood pressure, spirometry (a measure of lung function), heart rate, and pulse oximetry. We will also collect a urine sample and have you fill out some general health questionnaires. After this, we will familiarize you with the e-cigarette and rating scales we will be using to make sure you understand how to complete them.

During the lab session, you will sample 16 e-liquids total that contain different amounts of ingredients that can make e-cigarettes taste cooling. For each e-liquid, you will inhale from the e-cigarette two times taking three-second-long puffs. Then you will complete questionnaires about the e-cigarette experience. After waiting 10 minutes, you will repeat the same procedure for a second e-liquid. During that 10-minute period, you can drink water but should not eat or drink anything else. After waiting an additional 10 minutes, you will repeat the same procedure for a third condition, and so on until you have completed all sixteen conditions. The e-cigarettes **will not** contain nicotine and only you will be using the e-cigarettes you are given (they will not be used by others). If you feel any uncomfortable side effects during lab sessions (e.g., nausea, vomiting), you will be told that you can discontinue the puffing bout at any time.

During the lab session, we may ask you to wear a silicone smartband, similar to a smartwatch or fitbit. You will wear this on the same arm that you use to vape the e-cigarette. The smartband is used to monitor movement to track e-cigarette puffing behavior.

At the end of the lab session, we will ask you about all the flavors, but we will not tell you which flavors you tried in the e-cigarettes. This is because we do not want your knowledge of the flavors to influence your response or others' responses on questionnaires. If you are interested in learning what flavors were sampled in your e-cigarette, we will ask if you would like to be contacted after all 30 subjects have been completed and we can inform you at that time.

For your safety, the lab session will take place in a private environmentally controlled room, either at the J.B. Pierce Laboratory or at the WCRU, utilizing continuous floor-to-ceiling airflow to limit exposure. Instructions and communication will occur remotely using a 2-way audio system.

Optional Addendum for Data Repository

In addition, in this project, we would like to invite participants to participate in an additional portion of the project described below. Procedures noted below are in addition to those which you are informed about in this current consent and HIPAA authorization form.

Brief Description of the Project

Participation in a data repository for nicotine/tobacco studies.

In addition to the study procedures discussed in this consent form, we plan to share participant's data (tobacco/nicotine use, physical/mental health, other substance use, and questions regarding anxiety, depression, sleep, and pain as well as nicotine urinalysis results) into our data repository for analysis and to aid ongoing research (HIC 2000037658). A data repository holds research data and makes that data available for future use by the broader research community. This repository also has a screening component. You may have been referred to this study from that screening repository. If not, we may share your contact information, if you are interested, so you could be screened for participation in other similar studies.

Additional Information

- Information collected will be shared with the repository to contact you for other similar studies that you may wish to participate in and to aid in ongoing research.
- Limits to confidentiality. Research data collected will not be stored with your personal identifiers. Your information in the repository will be kept confidential and coded by a study number and not your name. However, there is a chance that confidentiality could be breached. We take confidentiality seriously and all data will be stored securely.

New Procedure(s)

Participation in the repository has no effect on this study. If you agree to participation in the repository, your procedures will remain the same, however, your data would be shared with the repository. In addition, by agreeing to the procedures in this consent addendum, you may be asked some screening questions to see if you may be interested and eligible to participate in other similar studies.

☐ I willingly consent to participate in the repository/sharing part of this study.

Initials: _____ Date: _____

☐ I do not wish to participate in the repository/sharing part of this study.

Initials: _____ Date: _____

What are the risks and discomforts of participating?

The potential risks related to the study are (1) COVID and tobacco product use, (2) e-cigarette exposure, (3) flavor exposure, (4) urine collection, (5) rating scales and assessments, (6) limits to confidentiality.

- 1) COVID & Tobacco Product Use.** Although the science on the relationship between getting COVID and using tobacco products like cigarettes and e-cigarettes is still not clear, you should remember that using tobacco products can lead to respiratory conditions like asthma. Therefore, if you use tobacco products and become infected with COVID-19, there is a potential that you could have worse health outcomes. Although scientific evidence is incomplete, some studies have suggested that use of e-cigarettes may add to your risk of getting COVID -19 and may contribute to the severity of illness if you do get the virus. We recommend you follow the CDC guidelines for the most up to date information about ways to reduce your risk for exposure to COVID-19. <https://www.cdc.gov/coronavirus/2019-ncov/index.html> If you develop symptoms for COVID-19 (fever, cough, shortness of breath, difficulty breathing, muscle aches, sore throat, congestion or runny nose, nausea or vomiting, diarrhea, new loss of taste or smell) or have known or suspected exposure, please self-isolate and contact your healthcare provider to discuss obtaining a test for COVID-19. Please inform research staff if you develop any of these symptoms or have

known/suspected exposure to COVID-19. If you become infected with COVID-19, we recommend you stop using all tobacco products.

- 2) **E-cigarette Exposure.** You were asked to participate in this study because you are a regular e-cigarette user who uses e-cigarettes with nicotine and flavors, therefore reducing your risk to any kind of adverse reaction to an e-cigarette. As an e-cigarette user, you are already using an e-cigarette to vape nicotine and flavors. The lab session will be conducted by trained research staff sensitive to tobacco users and trained to monitor any potential adverse effects.

E-cigarettes contain other chemicals besides nicotine and flavors including propylene glycol and vegetable glycerin. Some people are allergic to propylene glycol. You should not participate if you are allergic to propylene glycol. We will be using e-liquids that are created to be like commercially available e-cigarettes. The levels of propylene glycol and vegetable glycerin and the ratio of propylene glycol to vegetable glycerin in the research e-liquid are similar to the levels in commercial e-liquids. Some research has indicated that in large doses propylene glycol and vegetable glycerin can be harmful. All levels of e-liquids administered in this research study are below any potentially harmful levels. Research staff will monitor e-cigarette use during the lab session. If you feel any discomfort or need to stop for any reason, please let the researcher know. You can stop the study at any point.

We also want to make you aware of a lung illness called **E-cigarette and vaping lung injury (EVALI)**. There have been reported cases of severe pulmonary illness linked to “vaping” or e-cigarette use, called “E-cigarette or vaping product use associated lung injury (EVALI)”. EVALI was first discovered in late Summer 2019. These cases included symptoms such as coughing, shortness of breath, chest pain, fever, fatigue, nausea, vomiting, diarrhea, and/or abdominal pain. Some patients reported symptoms to have occurred over a few days and some reported to have occurred over a few weeks. Vaping-related disorders have ranged from mild to severe with hospitalization, intensive care with breathing machines and in some cases death. In most cases, but not all, people experiencing these symptoms were using cannabidiol (CBD) and marijuana (THC) e-liquids, and/or using e-cigarette devices and e-liquids that were mixed at home or purchased off market (such as purchasing an e-liquid or device on the street, not from a licensed retailer). Laboratory data show that Vitamin E Acetate, an additive in some THC-containing e-cigarette or vaping products is strongly linked to EVALI.

E-cigarette devices used in the study are Suorin iShare™ e-cigarettes (auto battery pod devices) and their e-liquid pods. The e-liquids that we will use in the current study will include ingredients including nicotine, propylene glycol, vegetable glycerin, and flavorants/flavoring agents. These ingredients are mixed at Yale Pharmacy and do not contain CBD, THC, or Vitamin E Acetate. Additionally, the e-cigarette devices (Suorin iShare) are commercially available outside of this study. The e-liquids are not; however, all individual ingredients in the e-liquids are commercially available.

Although there is much research devoted to EVALI, the exact cause of this lung injury remains unknown. Therefore, we ask you to abstain from using tobacco and THC-containing products from unknown sources, as they may not comply with standards set by Good Manufacturing Practices and could contain contaminants. The symptoms of EVALI can include cough, shortness of breath, chest pain, nausea, vomiting, stomach pain, diarrhea, fever, chills, or weight loss. If you feel sick or experience any of these symptoms, contact the study team as soon as possible.

We will assess your health at the intake to make sure you are healthy prior to participating and will continue to monitor your health closely during the study. If you experience any symptoms (such as abdominal pain, nausea, vomiting, diarrhea, cough, shortness of breath, chest pain) or have other concerns, please let us know and let your doctor know right away. Go to the emergency room right away if your symptoms are severe or increase rapidly. It is possible that the hospital may report cases of illness after using e-cigarettes to the State Health Department and the CDC. The report could contain the name and address of the person who is ill.

The Center for Disease Control (www.cdc.gov) has issued the following information on vaping:

- CDC and FDA recommend that people not use THC-containing e-cigarette, or vaping, products, particularly from informal sources like friends, family, or in-person or online dealers.
- Vitamin E acetate should not be added to any e-cigarette, or vaping, products. Additionally, people should not add any other substances not intended by the manufacturer to products, including products purchased through retail establishments.
- Adults using nicotine-containing e-cigarette, or vaping, products as an alternative to cigarettes should not go back to smoking; they should weigh all available information and consider using FDA-approved smoking cessation medications. If they choose to use e-cigarettes as an alternative to cigarettes, they should completely switch from cigarettes to e-cigarettes and not partake in an extended period of dual use of both products that delays quitting smoking completely. They should contact their healthcare professional if they need help quitting tobacco products, including e-cigarettes, as well as if they have concerns about EVALI.
- E-cigarette, or vaping, products (nicotine- or THC-containing) should never be used by youths, young adults, or women who are pregnant.
- Adults who do not currently use tobacco products should not start using e-cigarette, or vaping, products.
- THC use has been associated with a wide range of health effects, particularly with prolonged frequent use. The best way to avoid potentially harmful effects is to not use THC-containing e-cigarette, or vaping, products.
- Persons engaging in ongoing cannabis use that leads to significant impairment or distress should seek evidence-based treatment by a healthcare professional.

- 3) **Flavors in E-liquids.** At this time, there is little known about the short and long-term effects of inhaling flavorants. There may be unforeseen risks (such as allergic reactions). We will be using e-liquid recipes that are in line with those developed for commercial use and the flavor doses will be what is available in these e-liquids. Some research has indicated that certain chemicals used in some flavored e-liquids may be harmful in large doses. However, we will not be administering doses higher than what is available in commercial products. However, if you experience any side effects, you can stop the session at any point. Research staff will monitor e-cigarette use during the lab session. If you feel any discomfort or need to stop for any reason, please let the researcher know.
- 4) **Urine Collection.** Urine collections will be done at your in-person intake appointment to measure the amount of cotinine in your body and to test if you have recently used illicit “street” drugs. We may collect an additional urine sample at the lab visit if needed. Urine sample collection is not risky. If you are currently using illicit drugs, you may not be eligible to participate. If you are female, we will also administer a urine pregnancy test at all visits.

- 5) Rating scales and assessments.** These are all noninvasive and should add no risk. The major disadvantages are the time taken to complete them, and possible breach of confidentiality. You can choose not to answer any questions that may make you feel uncomfortable.
- 6) Limits to confidentiality.** We do not reveal any personal information collected as part of the research procedures, including your reported tobacco use and other substance use history. However, there is always the possibility that if you participate in the study, others, including friends, may become aware of your tobacco use status. If you do not feel comfortable with this, you should not participate in the project.

The research may involve risk that is currently unforeseeable.

How will I know about new risks or important information about the study?

We will tell you if we learn any new information that could change your mind about taking part in this study.

How can the study possibly benefit me?

There are no direct benefits of this study.

How can the study possibly benefit other people?

We expect that the results of the study, will benefit science and others through increasing our knowledge of how e-cigarette cooling flavors alter vaping behavior.

Are there any costs to participation?

You will not have to pay for taking part in this study. The only costs include transportation and your time coming to the study visits. Participants will not be responsible for the cost of the smartband if damaged.

Will I be paid for participation?

You will be paid for taking part in this study. You will be compensated up to \$150 for completing all parts of the study. We will use cash payments for taking part in this study. You will receive \$50 for the intake, \$90 for Lab session. In addition, you will be compensated \$10/visit for travel to the lab session. If you do not have a means of transportation, one will be provided to you. You will not receive travel payment if the study arranges a cab service to take you to your appointment. We can also validate parking in the Air Rights parking garage. You are responsible for paying state, federal, or other taxes for the payments you receive for being in this study. Taxes are not withheld from your payments.

Study Appointment	Payment	Travel Payment
Intake	\$50	-
Lab Visit 1	\$90	\$10

What are my choices if I decide not to take part in this study?

This is not a treatment study, and the alternative is to not participate or to participate with other research.

How will you keep my data safe and private?

We will keep information we collect about you confidential. We will share it with others if you agree to it or when we have to do it because U.S. or State law requires it. For example, we will

tell somebody if we learn that you are hurting a child or an older person. When the results of the research are published or discussed in conferences, no information will be included that would reveal your identity unless your specific consent for this activity is obtained.

This research is covered by a Certificate of Confidentiality from the National Institutes of Health. The researchers with this Certificate may not disclose or use information, documents, or biospecimens that may identify you in any federal, state, or local civil, criminal, administrative, legislative, or other action, suit, or proceeding, or be used as evidence, for example, if there is a court subpoena, unless you have consented for this use. Information, documents, or biospecimens protected by this Certificate cannot be disclosed to anyone else who is not connected with the research except, if there is a federal, state, or local law that requires disclosure (such as to report child abuse or communicable diseases but not for federal, state, or local civil, criminal, administrative, legislative, or other proceedings, see below); if you have consented to the disclosure, including for your medical treatment; or if it is used for other scientific research, as allowed by federal regulations protecting research subjects.

If you decide to be in the study, we will collect information that can identify you (like your name and telephone number). This information will not be stored with any information collected as part of the study. All information collected as part of the study will use a "Study ID" instead of your name to identify it. This is a set of numbers and letters that is not connected to your personal information. The principal investigator will keep a link that identifies you to your Study ID, and this link will be kept secure and available only to the principal investigator or selected members of the research team. Any information that can identify you will remain confidential. The research team will only give this coded information to others to carry out this research study. The link to your personal information will be kept for 7 years after the conclusion of the study, after which time the link will be destroyed and the data will become anonymous. The data will be kept in this anonymous form indefinitely.

All paper research materials will be stored in a locked cabinet in a locked office. All online materials will be stored in secure servers only accessible to those in the study.

When we publish the results of the research or talk about it in conferences, we will not use your name. If we want to use your name, we will ask you for your permission.

We may also share information about you with other researchers for future research, but we will not use your name or other identifiers. This may include biospecimens, which will not have identifiable information on them. We will not ask you for any additional permission.

What Information Will You Collect About Me in this Study?

The information we are asking to use and share is called "Protected Health Information." It is protected by a federal law called the Privacy Rule of the Health Insurance Portability and Accountability Act (HIPAA). In general, we cannot use or share your health information for research without your permission. If you want, we can give you more information about the Privacy Rule. Also, if you have any questions about the Privacy Rule and your rights, you can speak to Yale Privacy Officer at **203-432-5919**.

The specific information about you and your health that we will collect, use, and share includes:

- Research study records and visits
- Laboratory records of only those services provided in connection with this study (for example, urine tests).

How will you use and share my information?

We will use your information to conduct the study described in this consent form.

We may share your information with:

- The U.S. Department of Health and Human Services (DHHS) agencies
- Representatives from Yale University, the Yale Human Research Protection Program and the Institutional Review Board (the committee that reviews, approves, and monitors research on human participants), who are responsible for ensuring research compliance. These individuals are required to keep all information confidential.
- The U.S. Food and Drug Administration (FDA) This is done so that the FDA can review information about *tobacco products* involved in this research.
- The Principal Investigator of the study, Dr. Suchitra Krishnan-Sarin and members of the Research Team
- Data and Safety Monitoring Boards and others authorized to monitor the conduct of the Study

We will do our best to make sure your information stays private. But, if we share information with people who do not have to follow the Privacy Rule, your information will no longer be protected by the Privacy Rule. Let us know if you have questions about this. However, to better protect your health information, agreements are in place with these individuals and/or companies that require that they keep your information confidential.

Why must I sign this document?

By signing this form, you will allow researchers to use and disclose your information described above for this research study. This is to ensure that the information related to this research is available to all parties who may need it for research purposes. You always have the right to review and copy your health information in your medical record.

However, this is a double blinded treatment study (meaning you are not informed of the e-liquid flavor you are assigned) and if you sign this permission form, you will not be allowed to look at or copy your study related information until after the research is completed.

What if I change my mind?

The authorization to use and disclose your health information collected during your participation in this study will never expire. However, you may withdraw or take away your permission at any time. You may withdraw your permission by telling the study staff or by writing to **Dr. Suchitra Krishnan-Sarin, PhD at the 34 Park Street, New Haven, CT 06511.**

If you withdraw your permission, you will not be able to stay in this study but the care you get from your doctor outside this study will not change. No new health information identifying you will be gathered after the date you withdraw. Information that has already been collected may still be used and given to others until the end of the research study to ensure the integrity of the study and/or study oversight.

Who will pay for treatment if I am injured or become ill due to participation in the study?

If you are injured while on study, seek treatment and contact the study doctor as soon as you are able. Yale School of Medicine, Yale-New Haven Hospital, or the Connecticut Mental Health Center do not provide funds for the treatment of research-related injury. If you are injured as a result of your participation in this study, treatment will be provided. You or your insurance carrier will be expected to pay the costs of this treatment. No additional financial compensation for injury or lost wages is available. You do not give up any of your legal rights by signing this form.

What if I want to refuse or end participation before the study is over?

Taking part in this study is your choice. You can choose to take part, or you can choose not to take part in this study. You also can change your mind at any time. Whatever choice you make, you will not lose access to your medical care or give up any legal rights or benefits.

Not participating or withdrawing later will not harm your relationship with your own doctors or with this institution.

To withdraw from the study, you can call a member of the research team at any time and tell them that you no longer want to take part.

The researchers may withdraw you from participating in the research if necessary. The research team may decide to withdraw you if you do not follow directions of the study, we decide the study is not in your best interest, you become pregnant or intend to become pregnant during the study.

What will happen with my data if I stop participating?

When you withdraw from the study, no new health information identifying you will be gathered after that date. Information that has already been gathered may still be used and given to others until the end of the research study, as necessary to ensure the integrity of the study and/or study oversight.

If you withdraw from the study, biological samples (for example, urine samples) that have been collected from you can be withdrawn if they have not yet been analyzed or destroyed. If you want your samples withdrawn, you must tell the study team before or at the time you leave the study.

Who should I contact if I have questions?

Please feel free to ask about anything you don't understand.

If you have questions later or if you have a research-related problem, you can call the Principal Investigator at **203-974-7595**.

If you have questions about your rights as a research participant, or you would like to speak with someone other than the Principal Investigator or study team to discuss problems, concerns, or questions, or to obtain information or offer suggestions, you can call the Yale Institutional Review Boards at **203-785-4688** or email **hrpp@yale.edu**.

A description of this clinical trial will be available on <http://www.ClinicalTrials.gov>, as required by U.S. Law. This Web site will not include information that can identify you. At most, the Web site will include a summary of the results. You can search this Web site at any time.

Authorization and Permission

Your signature below indicates that you have read this consent document and that you agree to be in this study.

We will give you a copy of this form.

IRB Protocol# 2000035551

9-25-24 Version #5

_____ Participant Printed Name	_____ Participant Signature	_____ Date
_____ Person Obtaining Consent Printed Name	_____ Person Obtaining Consent Signature	_____ Date